- Raised $45.5M funding round led by Cormorant Asset Management, Mar 2021
- Raised $10M funding round, Jul 2024
- Raised $20M funding round, Dec 2019
About
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a first-in-class monoclonal antibody designed to neutralize CCL24 activity.
In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported encouraging results from a Phase 2 liver fibrosis biomarker study in NASH patients and an investigator study in patients with severe lung injury.
A global Phase 2 trial in primary sclerosing cholangitis patients is ongoing, with a top-line data readout targeted for the second half of 2024.
Funding history · 7 rounds · $90.5M total
Q&A
- What is Chemomab Therapeutics' primary focus?
- Chemomab Therapeutics is a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet needs.
- What is Chemomab Therapeutics' lead product candidate?
- Chemomab Therapeutics' lead product candidate is CM-101, a first-in-class monoclonal antibody designed to neutralize CCL24 activity, a soluble protein that promotes fibrosis and inflammation.
- What is the current status of CM-101's clinical trials?
- A global Phase 2 trial for CM-101 in primary sclerosing cholangitis patients is ongoing, with top-line data readout targeted for the second half of 2024.
- When was Chemomab Therapeutics founded?
- Chemomab Therapeutics was founded in November 2011.
- How many employees does Chemomab Therapeutics have?
- Chemomab Therapeutics has 11-50 employees.
- What is Chemomab Therapeutics' total funding raised to date?
- Chemomab Therapeutics has raised a total of $90.5 million USD.
- When was Chemomab Therapeutics' most recent funding round and who participated?
- In July 2024, Chemomab Therapeutics raised $10 million USD in a funding round that included OrbiMed.
- When did Chemomab Therapeutics go public on NASDAQ?
- Chemomab Therapeutics went public on NASDAQ in March 2021.
- Who is the Co-founder, CEO & CSO of Chemomab Therapeutics?
- Adi Mor is the Co-founder, CEO & CSO of Chemomab Therapeutics.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | chemomab.com |
|---|---|
| linkedin.com/company/18948873 |
Identifiers & details
| Founded | 2011-11 |
|---|---|
| Employees (exact) | 19 |
| Market cap | $10.2M |
| Status reason | Public on NASDAQ on Mar, 2021 |
Radar intelligence
Web history (Wayback)
| Domain | chemomab.com |
|---|
Certificate / subdomain footprint
| Subdomains | 12 |
|---|